Overview

Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and effectiveness of 2 doses of the investigational drug, lasofoxifene, compared to placebo (an inactive substance) in reducing new spinal fractures in women with osteoporosis.
Phase:
Phase 3
Details
Lead Sponsor:
Ligand Pharmaceuticals